Samsara BioCapital LLC Takes Position in Palvella Therapeutics (NASDAQ:PVLA)

Samsara BioCapital LLC bought a new position in Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 679,486 shares of the company's stock, valued at approximately $8,154,000. Palvella Therapeutics makes up approximately 1.1% of Samsara BioCapital LLC's investment portfolio, making the stock its 17th biggest holding. Samsara BioCapital LLC owned about 6.06% of Palvella Therapeutics as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of PVLA. Nantahala Capital Management LLC bought a new position in Palvella Therapeutics in the fourth quarter valued at $3,001,000. Blue Owl Capital Holdings LP purchased a new position in shares of Palvella Therapeutics during the 4th quarter valued at about $3,001,000. ADAR1 Capital Management LLC bought a new stake in Palvella Therapeutics in the 4th quarter worth approximately $1,736,000. BML Capital Management LLC bought a new stake in Palvella Therapeutics in the 4th quarter worth approximately $506,000. Finally, Renaissance Technologies LLC purchased a new stake in Palvella Therapeutics in the fourth quarter worth approximately $256,000. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Trading Down 3.7 %

Shares of PVLA stock traded down $0.90 during mid-day trading on Monday, reaching $23.56. 28,929 shares of the company's stock traded hands, compared to its average volume of 71,186. The firm's 50-day simple moving average is $24.56. The firm has a market cap of $259.61 million, a P/E ratio of -1.95 and a beta of 0.10. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $29.27.

Analyst Ratings Changes

PVLA has been the subject of several analyst reports. TD Cowen started coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They set a "buy" rating and a $44.00 price target for the company. Stifel Nicolaus began coverage on shares of Palvella Therapeutics in a report on Wednesday, March 26th. They issued a "buy" rating and a $45.00 target price on the stock. Jones Trading assumed coverage on shares of Palvella Therapeutics in a report on Tuesday, March 25th. They set a "buy" rating and a $45.00 price target for the company. HC Wainwright reissued a "buy" rating and set a $38.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, April 30th. Finally, Chardan Capital began coverage on shares of Palvella Therapeutics in a report on Wednesday, April 9th. They set a "buy" rating and a $50.00 target price for the company. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $44.43.

Insider Activity

In other Palvella Therapeutics news, Director George M. Jenkins acquired 2,500 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average cost of $20.13 per share, with a total value of $50,325.00. Following the transaction, the director now owns 183,171 shares of the company's stock, valued at $3,687,232.23. The trade was a 1.38 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 6.39% of the company's stock.

Palvella Therapeutics Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.